Pharmafile Logo
Pharmafocus logo
Advanced Search

Xenical

Showing 6 posts of 6 posts found.

Saxenda image

Novo Nordisk obesity drug shows added benefits

March 9, 2015
Sales and Marketing (liraglutide), Contrave, Novo Nordisk, Victoza, Xenical, liraglutide, obesity, saxenda, weight

New research by Novo Nordisk has suggested that its obesity drug Saxenda can help improve several other weight-related problems as …

News
Alli image

Alli bottles tampered with in US, drug recalled

March 27, 2014
Manufacturing and Production, Sales and Marketing Alli, FDA, GSK, Roche, Xenical, obesity, weight loss

GlaxoSmithKline has admitted that some bottles of its weight-loss drug Alli bought in the US have been tampered with. US …

News
FDA picture

Obesity drug supported by FDA panel

February 23, 2012
Sales and Marketing FDA, Qnexa, Vivus, Xenical, obesity

Vivus’ obesity drug Qnexa has been supported by an FDA panel, two years after it was knocked back by the …

News

GMP issues affect Mircera, Xenical production at Roche plant

January 31, 2012
Manufacturing and Production GMP, Mircera, Roche, Tamiflu, Xenical

Supply of two Roche products has been disrupted after an active pharmaceutical ingredient (API) production facility in the US was …

News
Obesity

Takeda obesity drug falters at phase II

March 18, 2011
Research and Development Alli, Amylin, Contrave, Meridia, Qnexa, Takeda, Xenical, lorcaserin, metreleptin, obesity, pramlintide

Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …

News

EMA under fire for blocking data access

June 8, 2010
Research and Development, Sales and Marketing Acomplia, Alli, EMA, Xenical, data

The European ombudsman has called for the European Medicines Agency to grant access to clinical study reports and trial protocols …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024